ePROElectronic Patient-Reported Outcome
An electronic Patient-Reported Outcome (ePRO) is a measure of how a patient feels or functions, captured directly from the patient on a validated electronic instrument. This guide explains where ePRO sits inside the broader eCOA family, FDA's PRO guidance and the more recent PFDD series, equivalence to validated paper instruments, BYOD considerations, ICH E6(R3) computerised-system expectations, and the data-integrity controls that turn an ePRO into defensible source data.
On this page · 6 sections
How does ePRO apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01Where ePRO sits inside eCOA
Clinical Outcome Assessments (COAs) are measures of how a patient feels, functions or survives, captured in a trial. COAs come in four flavours by who is doing the reporting: Patient-Reported Outcomes (PRO — the patient), Clinician-Reported Outcomes (ClinRO — the clinician), Observer-Reported Outcomes (ObsRO — a caregiver, parent), and Performance Outcomes (PerfO — a standardised task performed by the patient). When any of these are captured on an electronic device, the prefix 'e' is added — ePRO, eClinRO, eObsRO, ePerfO — and the umbrella term is eCOA.
ePRO is the largest and most discussed segment because it is the data source most often used to support labelling claims that are inherently patient-perspective: pain, fatigue, function, satisfaction, quality of life, symptom burden. FDA's December 2009 PRO guidance remains the foundational document; the more recent PFDD Guidance series (Guidances 1–4, with Guidance 3 on instrument selection and development finalised in June 2022) updates the conceptual framework for modern trials.
02FDA's PRO guidance and the equivalence question
FDA's 2009 PRO guidance lays out the qualification expectations for any instrument used to support a labelling claim: content validity (does the instrument measure the concept of interest in the target population?), construct validity (does it correlate with related measures?), reliability (does it give the same result on repeat administration when nothing has changed?), ability to detect change (is the minimum important difference defined?), and equivalence between paper and electronic modes if both are used.
Equivalence is the central historical question for ePRO. If a sponsor migrates a validated paper PRO to an electronic device, FDA expects evidence that the modes produce equivalent measurements — usually through a small equivalence study (cognitive debriefing plus a quantitative equivalence trial) following ISPOR Task Force recommendations. Minor formatting changes (typography, screen layout) typically need only usability testing; meaningful changes (item wording, response options, recall window) require full re-qualification.
03BYOD — bring your own device
Sponsor-provisioned devices were the historical norm — handheld study devices distributed to every participant — because they eliminated cross-device variability. BYOD (the participant uses their own smartphone) has accelerated since 2020 because it removes a logistics burden, removes a digital exclusion vector for participants comfortable with their own device, and is now broadly accepted by FDA when supported by appropriate equivalence and usability evidence.
BYOD-specific risks that the sponsor and ePRO vendor must address: screen-size variability (a question may layout differently on a 5.5" phone than a 6.7" tablet), OS version diversity, network connectivity gaps (data captured offline and synced later — what is the timestamp?), unique identification of the participant (the device is owned, but is the participant the one entering?), and security of the app on a non-sponsor-controlled device.
04Part 11, Annex 11 and ICH E6(R3)
An ePRO record is an electronic source record under 21 CFR Part 11 when no paper original exists — which is the normal case for a properly designed ePRO. The record must be attributable to the participant, contemporaneous with the patient experience, original (the electronic record is the source, not a transcription), and accurate (the instrument has been validated, the device renders the question as designed).
ICH E6(R3), finalised at Step 4 in January 2025, formalises the GCP expectations for computerised systems used in trials. Section 4 requires sponsors to maintain a documented assessment of every computerised system, scaled to its risk to participant rights, safety and data reliability. ePRO is squarely in scope. The same assessment expectations apply whether the ePRO is delivered on a sponsor device, BYOD, telehealth platform or hybrid.
05What to look for in an ePRO vendor
- A validated instrument library — the vendor has done the equivalence work for the standard instruments your protocol uses (EQ-5D, PROMIS, BPI, etc.) and can show the evidence package.
- Documented Part 11 controls — audit trail, e-signature, RBAC — not 'compliant by design'.
- Offline capture with correct timestamping — participant entry time stored separately from sync time.
- Multilingual support with linguistic validation evidence — translation and back-translation per ISPOR guidance.
- Sponsor-controlled data export with full audit-trail data, not just the summary value per visit.
- A vendor audit report (or SOC 2 + 21 CFR Part 11 audit) that the sponsor's QA can review before contracting.
06Common pitfalls
- Treating ePRO as a feature of the EDC instead of a Part 11–controlled system in its own right.
- Using the paper PRO's printed score-band cutoffs on the ePRO without re-validating equivalence.
- Allowing back-dating — letting participants enter yesterday's pain score 'just to keep the diary complete'. This is a contemporaneity failure and an inspection finding.
- Failing to document the device, OS version and app version associated with each entry — needed to investigate any subsequent rendering question.
- Using sync-time as the primary timestamp on offline-captured data.
Frequently asked questions
Q.Is an ePRO an investigational device?+
Usually no — when used as a measurement instrument in a trial it is a clinical outcome assessment tool, not a medical device. If the ePRO software itself drives clinical decisions or treatment (e.g., dosing adjustments based on PRO score), it may meet the definition of SaMD and require independent regulatory consideration.
Q.Can I use a generic survey tool as an ePRO?+
Generally no. Generic survey tools rarely meet Part 11 audit-trail and e-signature requirements, and have not been linguistically or psychometrically validated for the instruments you plan to deploy.
Q.Who owns the ePRO data?+
By contract, the sponsor — but the vendor processes it and the participant has rights under HIPAA / GDPR. The contract must address access, export, retention and destruction.
Q.Does ICH E6(R3) require a specific ePRO vendor qualification?+
It requires the sponsor to have a documented, risk-scaled assessment of every computerised system. Vendor qualification (audit, SOC reports, Part 11 audit) is how most sponsors meet that expectation for ePRO.
Q.Is paper PRO still acceptable?+
Yes, but increasingly rare. Most sponsors and many sites have shifted to ePRO for compliance (missing data, back-dating prevention), participant convenience, and operational efficiency.
Primary sources
- FDA — Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (Dec 2009)
- FDA — Patient-Focused Drug Development Guidance Series (Guidances 1–4)
- ICH E6(R3) — Good Clinical Practice (Step 4, January 2025)
- 21 CFR Part 11 — Electronic Records; Electronic Signatures
- ISPOR — eCOA Implementation Good Research Practices (Task Force Report, 2014)
Further reading
Want to see how ePRO could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.